Gene signatures of breast cancer progression and metastasis
Open Access
- 24 January 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Breast Cancer Research
- Vol. 13 (1), 201
- https://doi.org/10.1186/bcr2791
Abstract
Breast cancer is a heterogeneous disease. Patient outcome varies significantly, depending on prognostic features of patients and their tumors, including patient age, menopausal status, tumor size and histology, nodal status, and so on. Response to treatment also depends on a series of predictive factors, such as hormone receptor and HER2 status. Current treatment guidelines use these features to determine treatment. However, these guidelines are imperfect, and do not always predict response to treatment or survival. Evolving technologies are permitting increasingly large amounts of molecular data to be obtained from tumors, which may enable more personalized treatment decisions to be made. The challenge is to learn what information leads to improved prognostic accuracy and treatment outcome for individual patients.This publication has 75 references indexed in Scilit:
- HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trialBreast Cancer Research and Treatment, 2010
- Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencingProceedings of the National Academy of Sciences of the United States of America, 2010
- Management of breast cancer with targeted agents: importance of heterogenicityNature Reviews Clinical Oncology, 2010
- Tumor heterogeneity: Causes and consequencesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2010
- Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelinesBritish Journal of Cancer, 2009
- Micrometastases or Isolated Tumor Cells and the Outcome of Breast CancerThe New England Journal of Medicine, 2009
- HER-2/neu expression in primary and metastatic breast cancerBreast Cancer Research and Treatment, 2008
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerThe New England Journal of Medicine, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerThe New England Journal of Medicine, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001